Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Document › Details

ImaBiotech S.A.S.. (5/15). "Press Release: ImaBiotech to Conduct Pilot Study with GSK to Assess ImaBiotech's Multimaging Technology". Lille.

Organisations Organisation ImaBiotech S.A.S.
  Group ImaBiotech (Group)
  Organisation 2 GlaxoSmithKline plc (LSE: GSK, NYSE: GSK)
  Group GlaxoSmithKline (GSK) (Group)
Products Product Multimaging™ technology (combined Mass Spectrometry Imaging and Immuno-histology, ImaBiotech)
  Product 2 ADME services
Person Person Stauber, Jonathan (ImaBiotech 201206 CEO)

ImaBiotech will be conducting a pilot study with pharmaceutical company GlaxoSmithKline (GSK) on mass spectrometric derived imaging technology in the ADME and Toxicology fields.

ImaBiotech, a leading service provider for MALDI imaging focuses on quantification challenges and volumetric imaging data interpretation via the development of specially adapted multimodal imaging methods and dedicated software, known as Multimaging™. Multimaging™, a new Advanced Technology, significantly increases the capacity of Quantitative Mass Spectrometry Imaging, and classical histology techniques. It has the capability to quantitatively analyze the distribution of drug, metabolites and biomarkers at cellular level. This technology offers the potential to accelerate drug pharmacokinetic, pharmacology and toxicity studies.

Dr Jonathan Stauber, CEO of ImaBiotech commented, “We are very pleased with the initiation of a pilot study with a major pharmaceutical company. GSK's interest in assessing ImaBiotech's Multimaging technology further underscores the expertise of ImaBiotech in the imaging field and the potential benefits that Multimaging technology offers.”


Jonathan Stauber, PhD,
Chief Executive Officer
T:+33 (0) 320 164 091


Located in Europe (France), and North America (Cambridge, MA), ImaBiotech offers service with new imaging technologies, applications and software (Quantinetix™, Multimaging™). In order to accelerate drug development with innovative & proprietary imaging technologies, ImaBiotech offers Mass Spectrometry Imaging services to provide a cost effective solution to preclinical and clinical studies. This molecular technique is used for qualitative & quantitative efficacy and toxicity evaluations of drug candidates from the whole body to cell levels.

Record changed: 2016-03-28


Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81

More documents for ImaBiotech (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture [iito] Fighting Customers 650x80px

» top